Department of Radiation Oncology, University of Washington, Seattle, WA.
Departments of Radiation Oncology and Radiology, University of Washington, Seattle, WA.
Semin Radiat Oncol. 2018 Oct;28(4):309-320. doi: 10.1016/j.semradonc.2018.06.008.
Charged particle therapy with proton beam therapy (PBT) and carbon ion radiotherapy (CIRT) has emerged as a promising radiation modality to minimize radiation hepatotoxicity while maintaining high rates of tumor local control. Both PBT and CIRT deposit the majority of their dose at the Bragg peak with little to no exit dose, resulting in superior sparing of normal liver tissue. CIRT has an additional biological advantage of increased relative biological effectiveness, which may allow for increased hypofractionation regimens. Retrospective and prospective studies have demonstrated encouragingly high rates of local control and overall survival and low rates of hepatotoxicity with PBT and CIRT. Ongoing randomized trials will evaluate the value of PBT over photons and other standard liver-directed therapies and future randomized trials are needed to assess the value of CIRT over PBT.
采用质子束疗法 (PBT) 和碳离子放射疗法 (CIRT) 的带电粒子治疗已经成为一种有前途的放射治疗方式,可以最大限度地减少放射性肝毒性,同时保持高肿瘤局部控制率。PBT 和 CIRT 都将其大部分剂量沉积在布拉格峰处,几乎没有外照射剂量,从而使正常肝脏组织得到更好的保护。CIRT 还具有生物学优势,即相对生物学效应增加,这可能允许增加分割治疗方案。回顾性和前瞻性研究表明,PBT 和 CIRT 的局部控制率和总生存率高,肝毒性发生率低。正在进行的随机试验将评估 PBT 相对于光子和其他标准肝脏定向治疗的价值,未来还需要进行随机试验来评估 CIRT 相对于 PBT 的价值。